STSS - NASDAQ

Sharps Technology, Inc.

STSS·NASDAQ

$1.84

+1.1%

HealthcareMedical - Instruments & Supplies

Sharps Technology Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. The company was incorporated in 2017 and is based in Melville, New York.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$77.87M

EPS-11.1600

P/E Ratio-0.18

Earnings Date09/02/2026

269.08M

Assets

3579%

3Y+2173.0%

5Y+11955.0%

10Y+40582.0%

4.70M

Total Liabilities

-12%

3Y+114.0%

5Y+4537.0%

10Y+4572.0%

264.38M

Total Equity

13145%

3Y+2642.0%

5Y+12307.0%

10Y+47033.0%

Sharps Technology, Inc. Funding & Solvency Profile

STSS · NASDAQ

Current Assets

Cash & Cash Equivalents10.38M

Net Receivables711.96K

Inventory645.27K

Other Current Assets-7.17M

Total Current Assets11 M

Non-Current Assets

Property, Plant & Equipment81.17K

Goodwill & Intangible Assets250.11M

Long-Term Investments0.00

Other Non-Current Assets-250.11M

Total Non-Current Assets-250029958

Total Assets

269.08M

Financial Health Analysis

Current Ratio

2.39x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.02x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

7 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

4% Current

Capital-intensive business with significant long-term investments in property, equipment, or intangibles.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Sharps Technology, Inc. Balance Sheet

STSS • NASDAQ

Sharps Technology, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	10.4M	864K	3M	4.2M	1.5M	1.8M	635.5K
Cash & Short-Term Investments	10.4M	864K	3M	4.2M	1.5M	1.8M	635.5K
Net Receivables	712K	102.5K	47.9K	0.0	0.0	0.0	0.0
Accounts Receivables	712K	102.5K	47.9K	0.0	0.0	0.0	0.0
Inventory	645.3K	1.9M	1.7M	185.8K	122K	0.0	0.0
Prepaids	6.7M	89.7K	68.6K	66.7K	8K	50K	0.0
Other Current Assets	-7.2M	250K	0.0	0.0	0.0	0.0	0.0
Total Current Assets	11.2M	3.2M	4.8M	4.4M	1.6M	1.8M	635.5K
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	81.2K	4M	6.8M	7.3M	3.8M	316.9K	25.9K
Intangible Assets	250.1M	32.5K	52.5K	62.5K	0.0	0.0	0.0
Goodwill & Intangible Assets	250.1M	32.5K	52.5K	62.5K	0.0	0.0	0.0
Other Non-Current Assets	-250.1M	72.2K	76.1K	12.4K	529.9K	75K	0.0
Total Non-Current Assets	81.2K	4.1M	7M	7.4M	4.3M	391.9K	25.9K
Other Assets	257.8M	0.0	0.0	0.0	0.0	0.0	0.0
Total Assets	269.1M	7.3M	11.8M	11.8M	5.9M	2.2M	661.4K
LIABILITIES
CURRENT LIABILITIES
Total Payables	590.7K	976.5K	794.1K	543.2K	804.1K	101.2K	100.5K
Accounts Payable	590.7K	976.5K	794.1K	543.2K	804.1K	101.2K	100.5K
Accrued Expenses	0.0	346.5K	476.1K	311.5K	677K	0.0	0.0
Short Term Debt	3.1M	3.8M	0.0	0.0	700K	0.0	0.0
Other Current Liabilities	1M	98.9K	2.4M	1.2M	585K	0.0	0.0
Total Current Liabilities	4.7M	5.2M	3.7M	2M	2.8M	101.2K	100.5K
NON-CURRENT LIABILITIES
Deferred Tax Liabilities (Non-Current)	0.0	132K	162K	192K	0.0	0.0	0.0
Total Non-Current Liabilities	0.0	132K	162K	192K	0.0	0.0	0.0
Total Liabilities	4.7M	5.3M	3.9M	2.2M	2.8M	101.2K	100.5K
SHAREHOLDERS' EQUITY
Common Stock	2.9K	205.0	1.5K	941.0	519.0	460.0	1.4K
Additional Paid-In Capital	581.3M	36.4M	32.5M	24.7M	13.8M	8.1M	0.0
Retained Earnings	-316.9M	-34.4M	-25.1M	-15.3M	-10.7M	-6M	-3.7M
Accumulated Other Comprehensive Income/Loss	0.0	23.3K	591.8K	214.3K	0.0	0.0	0.0
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	-32.5K	0.0	4.2M
Total Stockholders' Equity	264.4M	2M	7.9M	9.6M	3.1M	2.1M	560.9K
Total Equity	264.4M	2M	7.9M	9.6M	3.1M	2.1M	560.9K
SUMMARY
Total Liabilities & Equity	269.1M	7.3M	11.8M	11.8M	5.9M	2.2M	661.4K
Total Debt	3.1M	3.8M	0.0	0.0	700K	0.0	0.0
Net Debt	-7.3M	2.9M	-3M	-4.2M	-779.2K	-1.8M	-635.5K
Shares Outstanding	28,226,151	28,226,151	28,226,151	28,226,151	28,226,151	28,226,151	28,226,151

SEC Filings

STSS - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 29, 2026	May 29, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 14, 2026	March 31, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 31, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 23, 2026	February 17, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 16, 2026	January 15, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 16, 2026	January 15, 2026	2026	View Filing
S-3/A S-3/A (Amended) N/A	December 23, 2025	December 23, 2025		View Filing
8-K 8-K 2025 N/A	December 23, 2025	December 19, 2025	2025	View Filing
S-3/A S-3/A (Amended) N/A	December 23, 2025	December 23, 2025		View Filing
10-Q 10-Q 2025 Q3 Q3	November 14, 2025	September 30, 2025	2025	View Filing

Showing 1 to 10 of 130 filings

Related Guides

Blog Categories

Continue your STSS research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.